SynOx Therapeutics: Emactuzumab designated as an Orphan Medicinal Product in Europe

TGCT is a debilitating disease that often impacts patients in the prime of their lifeDesignation to include both localized and diffuse forms of the diseaseDUBLIN, Aug. 31, 2022 /PRNewswire/

Related Keywords

Ireland ,Dublin ,Gray Barlow ,Kostenloser Wertpapierhandel ,Acta Orthopaedica ,Prnewswire Synox Therapeutics Limited ,European Medicines Agency ,Synox Therapeutics ,Tenosynovial Giant Cell Tumour ,Chief Executive Officer ,Celleron Therapeutics ,Giant Cell Tumour ,Synox ,Herapeutics ,Mactuzumab ,Esignated ,Orphan ,Medicinal ,Product ,Europe ,